Evidence map›Paper›PMID 30912248›Full record

ArticlePediatric diabetes2019

Prevalence, characteristics, and diabetes management in children with comorbid autism spectrum disorder and type 1 diabetes.

Kelly R Stanek, Erin M Youngkin, Laura L Pyle, Jennifer K Raymond, Kimberly A Driscoll, Shideh Majidi

Open access · greenAbstract read
In one paragraph

Article in Pediatric diabetes, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. The Prevalence of Diabetes in Autistic Persons: A Systematic Review.Clinical practice and epidemiology in mental health : CP & EMH · 2020
    Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Kelly R StanekBarbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
Erin M YoungkinBarbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
Laura L PyleBarbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
Jennifer K RaymondCenter for Endocrinology, Diabetes, and Metabolism, Children's Hospital Los Angeles, Los Angeles, California.
Kimberly A DriscollBarbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
Shideh MajidiBarbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, Colorado.ORCID 0000-0003-4899-3040
University of Colorado Anschutz Medical Campus · USChildren's Hospital of Los Angeles · US

Funding

K12 Career DevelopmentK12DK094712 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI STECK, ANDREA · 2011 to 2021
$4.5M
NIDDK NIH HHS 5K12DK094712NIDDK NIH HHS K12 DK094712
6 · The paper itself

Abstract

objectiveTo determine autism spectrum disorder (ASD) prevalence within our pediatric type 1 diabetes (T1D) clinic population and determine clinical characteristics and technology used by individuals with both ASD and T1D compared to matched controls with T1D alone and compared to our overall pediatric T1D clinic.

methodsMedical chart review showed 30 individuals with both ASD and type 1 diabetes (ASD + T1D). Controls (n = 90) were matched for age, sex, race/ethnicity, and T1D duration. ASD + T1D was compared to both matched controls and the pediatric T1D clinical population.

resultsASD prevalence in the pediatric T1D population was 1.16% (CI 0.96-1.26). Compared to the T1D clinic, ASD + T1D had more males (93% vs 52%; P < 0.0001), lower hemoglobin A1c (HbA1c) (8.2% vs 8.9%; 66 vs 74 mmol/mol; P = 0.006), and lower insulin pump (CSII) use (37% vs 56%; P < 0.0001). No differences were found between ASD + T1D and matched controls in HbA1c or blood glucose checks per day. The ASD + T1D group was less likely to use CSII than matched controls (37% vs 61%; P = 0.03). HbA1c did not change after CSII initiation in ASD + T1D, but increased for matched controls.

conclusionsPrevalence of ASD in the pediatric T1D population is comparable to the general population in Colorado. Individuals with ASD may experience barriers limiting CSII use, but achieve equivalent glycemic control compared to those without ASD. CSII may be more effective in maintaining lower HbA1c over time in those with ASD than in those without ASD.

Indexed as

AdolescentAutism Spectrum DisorderChildColoradoDiabetes Mellitus, Type 1FemaleHumansInsulin Infusion SystemsMalePrevalenceRetrospective Studiesautistic disorderdiabetes mellitusdisease managementpediatricstype 1

Identifiers

PMID30912248
PMCPMC6658086
OpenAlexW2924511967

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.